---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-21-000021"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2021-10-04T23:59:59+00:00"
generated_at: "2026-06-28T23:30:25.018195+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arcutis submits NDA to FDA for roflumilast cream in plaque psoriasis

## Summary
- Submitted NDA for roflumilast cream (ARQ-151) to FDA for mild-to-severe plaque psoriasis.
- Indication covers adults and adolescents; submission date October 4, 2021.
- Roflumilast cream is a topical PDE4 inhibitor, a novel mechanism for psoriasis.

## SEC filing metadata
- accession: 0001787306-21-000021
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2021-10-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730621000021/0001787306-21-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730621000021/arqt-20211004.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-21-000021
- JSON: https://secwatch.observer/filing/0001787306-21-000021.json
- Plain text: https://secwatch.observer/filing/0001787306-21-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.